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Abstract
Background: Schistosomiasis continues to be a significant public health problem. This disease affects 200 million people
worldwide and almost 800 million people are at risk of acquiring the infection. Although vaccine development against this
disease has experienced more failures than successes, encouraging results have recently been obtained using membrane-
spanning protein antigens from the tegument of Schistosoma mansoni. Our group recently identified Sm29, another antigen
that is present at the adult worm tegument surface. In this study, we investigated murine cellular immune responses to
recombinant (r) Sm29 and tested this protein as a vaccine candidate.
Methods and Findings: We first show that Sm29 is located on the surface of adult worms and lung-stage schistosomula
through confocal microscopy. Next, immunization of mice with rSm29 engendered 51%, 60% and 50% reduction in adult
worm burdens, in intestinal eggs and in liver granuloma counts, respectively (p,0.05). Protective immunity in mice was
associated with high titers of specific anti-Sm29 IgG1 and IgG2a and elevated production of IFN-c, TNF-a and IL-12, a typical
Th1 response. Gene expression analysis of worms recovered from rSm29 vaccinated mice relative to worms from control
mice revealed a significant (q,0.01) down-regulation of 495 genes and up-regulation of only 22 genes. Among down-
regulated genes, many of them encode surface antigens and proteins associated with immune signals, suggesting that
under immune attack schistosomes reduce the expression of critical surface proteins.
Conclusion: This study demonstrates that Sm29 surface protein is a new vaccine candidate against schistosomiasis and
suggests that Sm29 vaccination associated with other protective critical surface antigens is the next logical strategy for
improving protection.
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Introduction
Schistosomiasis mainly occurs in developing countries and is the
most important human helminth infection in terms of global
mortality. This parasitic disease affects more than 200 million people
worldwide causing more than 250,000 deaths per year [1].
Furthermore, schistosomiasis causes up to 4.5 million DALY
(disability adjusted life year) losses annually [2]. Recently, King et
al [3] have associated schistosomiasis with anemia, pain, diarrhea,
exercise intolerance, and under-nutrition that results from chronic
infection. Current schistosomiasis control strategies are mainly based
on chemotherapy but, in spite of decades of mass treatment, the
number of infected people remains constant [4]. Extensive endemic
areas and constant reinfection of individuals together with poor
sanitary conditions in developing countries make drug treatment
alone inefficient [5]. Many consider that the best long-term strategy
to control schistosomiasis is through immunization with an anti-
schistosomiasisvaccine combinedwithdrugtreatment[6].A vaccine
that induces even a partial reduction in worm burdens could
considerably reduce pathology and limit parasite transmission [7].
Sm29 protein has been characterized by our group [8], proving
to be a membrane-bound antigen on adult worms that is strongly
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individuals and patients resistant to re-infection living in endemic
areas for schistosomiasis in Brazil. Recent studies, using micro-
arrays and RT-PCR, showed that Sm29 is among the 16% most
highly expressed genes in S. mansoni, and probably serves an
important function in the surface biology of this parasite [9,10].
Proteomic analysis of the S. mansoni tegument composition
identified Sm29 as one of the integral proteins to be consistently
found in the outer surface [11]. Therefore, the next step would be
to investigate humoral and cellular immune responses induced by
Sm29 in vaccinated mice and protection studies.
Herein, we determined that Sm29 is present on the tegument of
lung-stage and male and female adult worms of S. mansoni by
confocalmicroscopy.Besides,rSm29inducedaTh1-typeofimmune
response inmiceand reduction inwormburden and liver pathology.
Methods
Mice and parasites
C57BL/6 and TLR4 KO female mice, 6–8 weeks old, were
obtained from the Federal University of Minas Gerais (UFMG)
animal facility. All procedures involving animals were approved by
the local Ethics Committee on Animal Care (CETEA-UFMG).
Cercariae of S. mansoni (LE strain) were maintained routinely in
Biomphalaria glabrata snails at Rene Rachou Research Center
(Fiocruz, Brazil) and prepared by exposing infected snails to light
for 2 hrs to induce shedding of parasites. Cercarial numbers and
viability were determined using a light microscope prior to
infection. The protocols involving animals used in this study were
approved by the Federal University of Minas Gerais Ethics
Committee in Animal Experimentation (CETEA No. 023/2005).
Antigen preparation
The recombinant Sm29 was produced and purified as described
previously [8]. Briefly, the Sm29 cDNA fused with a C-terminal 6x
histidine was produced in E.coli using the pET21a expression
vector (Novagen, NJ, USA). The recombinant Sm29 was purified
in an affinity column and dialyzed against PBS pH 7.0.
Immunolocalization of Sm29 in male, female and lung-
stage schistosomula of S. mansoni
Adult worms used in confocal microscopy studies were
recovered from perfused mice and lung-stage schistosomula were
prepared according to the method described by Harrop & Wilson
[12]. Parasites fixed in Omnifix II (Ancon Genetics, St Petersburg,
FL, USA) were used in whole mount or in section assays. For
sections assays, 7 mm slices were deparaffinized with xylol series.
Parasites were blocked with 1% BSA in PBST (Tween 20 0.05%)
for 1 hr and incubated with anti-rSm29 serum diluted 1:20 in
blocking buffer. Serum from non-immunized mice was used as a
negative control. Samples were washed three times with PBST and
incubated with anti-mouse IgG antibody conjugated to Alexa
Fluor 594 (Molecular Probes, CA, USA) diluted 1:100 in blocking
buffer containing Phalloidin Alexa Fluor 488 (Molecular Probes)
to stain actin microfilaments. The samples were washed four times
and mounted in antifade reagent (Prolong gold–Molecular
Probes). For whole mount assays, parasites were blocked with
1% BSA, 0.1% Triton X-100, 0.1% azide in PBS for two hours at
4uC under agitation. Blocked parasites were incubated with anti-
Sm29 serum diluted 1:80 in the blocking buffer during 16hrs at
4uC under agitation. Samples were washed six times with PBST
and incubated with anti-mouse and phalloidin, both diluted 1:300,
during 4 hours at 4uC under agitation. The samples were washed
five times and mounted in 90% glycerol and 10% TRIS, pH 9.0.
The parasites were visualized in a Zeiss 510 Meta confocal
microscope using an immersion objective. All the parameters and
microscope settings used were maintained throughout the process.
Tegument purification
Cercariae obtained from Biomphalaria glabrata snails exposed to
light for two hours were transformed mechanically in skin-stage
schistosomula according to Ramalho-Pinto et al [13]. First,
cercariae were incubated on ice for 30 minutes and centrifuged
for 3 minutes, 1000 rpm, 4uC. The cercariae were resuspended in
1ml of cold ELAC (Earle’s salts plus lactalbumin hydrolysate)
contain 0.5% lacto albumin, 1% penicillin/streptomycin and
0.17% glucose. The tails were broken by vortex in high speed
during 2 minutes. After this, the tails were removed through six
washes with ELAC. The schistosomula were incubated for 1 hour
and 30 minutes at 37uC in ELAC and washed with apyrogenic
physiologic saline. For the tegument removal, the schistosomula
were submitted to vortex using high speed, two times of eight
minutes each, in a CaCl2 0.3 M solution. The sample was
centrifuged at 1000 rpm for 1 minute. The supernatant was
collected and centrifuged at 26500 rpm for 1 hour at 4uC. The
pellet was dialyzed against physiologic saline 1.7%.
Western blot analysis
Two micrograms of purified skin-stage schistosomula tegument
were submitted to SDS- PAGE 12%, transferred to a nitrocellulose
membrane (Millipore) and blocked 16 hours at room temperature
withTBST(0.5MNaCl,0.02MTrispH 7.5,0.05%tween,5%skim
milk). The membranes were washed tree times with TBST and
probed with anti-Sm29 or naive mice serum diluted 1:500 in TBST
for 4 hours at room temperature. The membranes were washed six
times and probed one hour with anti-mouse IgG conjugated to
alkaline phosphatase (Invitrogen) diluted 1:10000 in TBST. After six
washes, the membranes were developed using ECF subtract (GE
Healthcare) and visualized in a Storm apparatus (GE Healthcare).
Author Summary
Schistosomiasis is the most important human helminth
infection in terms of morbidity and mortality. Although the
efforts to develop a vaccine against this disease have
experienced failures, a new generation of surface antigens
revealed by proteomic studies changed this scenario. Our
group has characterized the protein Sm29 described
previously as one of the most exposed and expressed
antigens in the outer tegument of Schistosoma mansoni.
Studies in patients living in endemic areas for schistoso-
miasis revealed high levels of IgG1 and IgG3 anti-Sm29 in
resistant individuals. In this study, confocal microscope
analysis showed Sm29 present in the surface of lung-stage
schistosoluma and adult worms. Recombinant Sm29, when
used as vaccine candidate, induced high levels of
protection in mice. This protection was associated with a
typical Th1 immune response and reduction of worm
burden, liver granulomas and in intestinal eggs. Further,
microarray analysis of worms recovered from vaccinated
mice showed significant down-regulation of several genes
encoding previously characterized vaccine candidates and/
or molecules exposed on the surface, suggesting an
immune evasion strategy of schistosomes under immune
attack. These results demonstrated that Sm29 as one of
the important antigens with potential to compose a
vaccine against schistosomiasis.
Sm29 Is a Protective Tegument Antigen of S. mansoni
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Six to eight week old female C57BL/6 mice were divided into
two groups of ten mice each. Mice were subcutaneously injected in
the nape of the neck with 25 mg rSm29 on days 0, 15 and 30.
Sm29 protein concentration for vaccination was determined as
previously described [14]. The recombinant protein was formu-
lated with Freund’s adjuvant (complete Freund’s adjuvant/CFA
for the first immunization and incomplete Freund’s adjuvant/IFA
for the boosters). In the control group, PBS with Freund’s adjuvant
was administered using the same immunization protocol.
Challenge infection and worm burden recovery
Fifteen days after the last boost, mice were challenged through
percutaneous exposure of abdominal skin for 1 h in water
containing 100 cercariae (LE strain). Forty-five days after
challenge, adult worms were perfused from the portal veins.
Two independent experiments were performed to determine
protection levels. The protection was calculated by comparing the
number of worm recovered from each vaccinated group with its
respective control group, using the formula:
PL~
WRCG{WREG
WRCG
|100
where PL=protection level, WRCG=worms recovered from
control group, and WREG=worms recovered from experimental
group.
Oogram and histophatological analysis
Following perfusion for the recovery of the schistosomes,
fragments of the intestine (terminal ileum) from each animal were
separated and transferred to the Petri dishes containing saline as
previously demonstrated [15]. The intestines were opened
lengthwise and the excess mucus was removed. One-centimeter
fragments were weighed and placed between a glass slide and a
plastic cover. The preparation was inverted and pressed on a
rubber surface padded with filter paper. Then, the slices were
examined with a microscope (100 x) and all the eggs were counted.
Quantitative oograms were obtained, using the formula: number
of eggs/grams of tissue=number of eggs in intestinal fragment/
weight of fragment in mg. A qualitative oogram evaluation was
performed, in which the developmental stages of the eggs were
classified as described previously.
The liver fragments were collected from the same animals
analyzed in oogram studies and fixed in 10% paraformaldehyde.
The fragments were processed for paraffin embedding and
histopathological sections performed using microtome at 6–7 mm
and stained in a slide with hematoxilin-eosin (HE). The number of
granulomas was obtained from the liver sections using 10x
objective in a microscope. The area from each liver section was
calculated using capture in scanner followed by analysis in the
KS300 software connected to a Carl Zeiss image analyzer.
Measurement of specific anti-Sm29 antibodies
Following immunization,sera of ten micefrom eachexperimental
group were collected at two-week intervals. Measurement of specific
anti-Sm29 antibodies was performed using indirect ELISA. Max-
isorp 96-well microtiter plates (Nunc, Denmark) were coated with
5 mg/ml rSm29 in carbonate-bicarbonate buffer, pH 9.6 for 16 h at
4uC,thenblockedfor2atroomtemperaturewith200 ml/wellPBST
(phosphate buffer saline, pH 7.2 with 0.05% Tween-20) plus 10%
FBS (fetal bovine sera). One hundred microliters of each serum
diluted 1:100 in PBST was added per well and incubated for 1 h at
room temperature. Plate-bound antibody was detected by peroxi-
dase-conjugated anti-mouse IgG, IgG1 and IgG2a (Southern
Biotechnology, CA, USA) diluted in PBST 1:10000, 1:5000 and
1:2000, respectively. Color reaction was developed by addition of
100 ml per well of 200 pmol OPD (o-phenylenediamine, Sigma) in
citratebuffer,pH 5.0 plus0.04%H2O2for10 minandstopped with
50 ml of 5% sulfuricacidper well.The plateswereread at 495 nm in
an ELISA plate reader (BioRad, Hercules, CA).
Cytokine analysis
Cytokine experiments were performed using splenocyte cultures
from individual mice immunized with rSm29 plus CFA/IFA (n=5
for each group). Splenocytes were isolated from macerated spleens
of individual mice 10 days after the third immunization and
washed twice with sterile PBS. After washing, the cells were
adjusted to 1610
6 cells per well for IL-4, IL-10, IFN-c and TNF-a
assays in RPMI 1640 medium (Gibco, CA, USA) supplemented
with 10% FBS, 100 U/ml penicillin G sodium, 100 mg/ml
streptomycin sulfate, 250 ng/ml amphotericin B. Splenocytes
were maintained in culture with medium alone or stimulated with
rSm29 (25 mg/ml) or concanavalin A (ConA) (5 mg/ml) as
previously described [14,16]. The 96-well plates (Nunc) were
maintained in an incubator at 37uC with 5% CO2. For cytokine
assays polymyxin B (30 mg/ml) was added to the cultures and this
treatment completely abrogate the cytokine response to LPS as
previously described [17]. Culture supernatants were collected
after 24 h of ConA stimulation, 48 h of rSm29 stimulation for IL-
4 and TNF-a analysis and 72 h of rSm29 stimulation for IL-10
and IFN-c. The assays for measurement of IL-4, IL-10, IFN-c and
TNF-a were performed using the Duoset ELISA kit (R&D
Diagnostic) according to the manufacturer’s directions.
Innate immune responses were assessed using peritoneal
macrophages culture obtained from C57BL/6 and TLR4 KO
mice that had received an intra-peritoneal injection of thioglyco-
late four days earlier. The macrophages were recovered through
peritoneal washes with PBS and adjusted to 1610
6 cells per well
for IL-12p40 assays in RPMI 1640 medium (Gibco) supplemented
with 5% FBS, 100U/ml penicillin G sodium and 100 mg/ml
streptomycin sulfate. Macrophages were maintained in culture
with medium alone or stimulated with rSm29 (25 mg/ml) or LPS
purified from E. coli (1 mg/ml). Culture supernatants were
collected after 24 hrs of stimulation. The assays for measurement
of IL-12p40 were performed using the Duoset ELISA kit (R&D
Diagnostic) according to the manufacturer’s directions.
Microarray analysis of gene expression in S. mansoni
worms
Total RNA was obtained using Trizol reagent (Invitrogen)
according to the manufacturer’s instructions. RNA was quantified
using the Nanodrop ND-1000 UV/Vis spectrophotometer and
RNA integrity was checked by electrophoresis with an Agilent
2100 Bioanalyzer. One microgram of total RNA from each
sample was amplified using the T7-RNA polymerase-based linear
amplification protocol. Three micrograms of aminoallyl-modified
amplified RNA was labeled with Cy3 or Cy5 by indirect labeling
(GE Healthcare).
The Cy3- and Cy5-labeled RNA samples were combined and
hybridized overnight to cDNA microarray slides using ASP
hybridization chambers (GE Healthcare) at 42uC and the protocols
were followed as recommended by manufacturer [18]. Slides were
scanned at 5 mm resolution, 100% laser power (GenePix 4000B,
Molecular Devices, USA) and PMT levels were adjusted in order to
obtainsimilaraverageintensitiesofredandgreensignals.Eacharray
contained 4,000 different elements, spotted in duplicate on the left
Sm29 Is a Protective Tegument Antigen of S. mansoni
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cDNA clones spotted on the arrays were selected to represent 4,000
unique transcripts that were identified in the large-scale S. mansoni
transcriptome project [19].
RNA from the pool of adult worms recovered from mice that
had been immunized with the rSm29 vaccine (test sample) was
hybridized against RNA from control adult worms recovered from
mice treated only with adjuvant (control sample). Each assay
consisted of two separate hybridizations, the first with Cy5-labeled
test sample and Cy3-labeled control, and the second with dye-
swap in order to account for dye bias; for each probe, the intensity
of the test sample was computed as the average intensity of the
Cy5 and Cy3 measurements; the same was computed for the
control sample. Each assay provided two average values for the
test and two for the control, arising from the duplicated copies of
each gene that are spotted on the left and right halves of the glass
slides [18]. A total of four hybridizations were performed,
corresponding to two sets of technical replicate assays. Thus, a
total of four different average intensity values for the test and four
for the control sample were obtained for each probe on the array.
Data was extracted from images using the Array Vision 8.0
program. We used a locally weighted linear regression (LOWESS)
algorithm to correct for systematic bias due to small differences in
the labeling and/or detection efficiencies between the fluorescent
dyes [20]. Normalized log2 ratios of the intensities of test/control
were used for the statistical analysis with the Significance Analysis
of Microarrays tool (SAM) using a 0.14% false discovery rate
(FDR), which corresponds to a q-value (analogous to the t-test p-
value) of q,0.01, to find significant differentially expressed genes
[21]. Genes determined in the previous step were filtered using a
median fold-change $1.5 as cutoff, where fold-change=2 ˆ|log2
(test/control)|. The fold-change filter was applied after identifica-
tion of significant differentially expressed genes with the use of
SAM, therefore avoiding the bias caused by the use of arbitrary
thresholds to trim datasets before significance testing [22].
Putative identity of regulated genes
Regulated genes were manually annotated by similarity using
BLASTx and the GenBank nr database with a cut-off e-
value=10
210. Sequences were placed into four categories
according to the similarity matches, as follows: tegument proteins,
membrane proteins, receptor interacting proteins, lipid metabo-
lism and other functions.
Real-time RT-PCR
Total RNA was extracted with Trizol reagent (Invitrogen),
according to the manufacturer’s instructions. RNA samples were
treated with DNAse, purified and concentrated using RNeasy
Micro Kit (QIAGEN), following the manufacturer instructions
and 1.5 mg of each sample was reverse transcribed using the
SuperScriptH III First-Strand Synthesis SuperMix (Invitrogen).
Specific primer pairs (Table S2) were designed by Primer Express
Program using default parameters (Applied Biosystem) and
arbitrarily named primers 1 and 2. Real-time RT-PCRs were
run in triplicates in a volume of 20 ml containing 10 ml of Sybr
Green PCR Master Mix (Applied Biosystem), 160 nmol of each
primer (primers 1 and 2), 0.30 ml cDNA from reverse transcrip-
tion. Real-time RT-PCR was performed with the 7300 Real-Time
PCR System (Applied Biosystem) using the following cycling
parameters: 60uC for 10 min, 95uC for 10 min, 40 cycles of 95uC
for 15 sec and 60uC for 1 min, and a dissociation stage of 95uC for
15 sec, 60uC for 1 min, 95uC for 15 sec, 60uC for 15 sec. Real
time data was normalized in relation to the level of expression of
actin. p-values were determined for the triplicates with Student’s t-
test, using one tail distribution and heteroscedastic variance.
Microarray data public deposition information
All microarray data were deposited in the GEO public database
under Accession No. GSE10777.
Statistical analysis
Statistical analysis was performed with Student’s t-test for
comparison between two experimental groups using the software
package GraphPad Prism.
Results
Sm29 is a tegument protein of S. mansoni
In the present study, we demonstrated the localization of Sm29
in the male and female adult worms and also in the lung-stage
schistosomula of S. mansoni using specific antibodies to rSm29
produced in E. coli. The native Sm29 was located exclusively on
the surface of lung-stage schistosomula and male adult worms of S.
mansoni (Fig. 1A, B, C, D, and Video S1). The female adult worm
showed Sm29 located on the surface and also in internal tissues
(Fig. 1E). Confocal microscopy analysis also revealed that Sm29 is
not present in the cercariae stage of S. mansoni (Figure S1), as
expected from the absence of mRNA coding for this antigen in
cercariae cDNA library [8]. Additionally, we detected Sm29 in the
purified tegument fraction of the skin-stage schistosomula by
western blot analysis using specific antibodies to rSm29 (Fig. 2).
Antibody profile following mice immunization
To evaluate the level of specific IgG, IgG1 and IgG2a
antibodies to Sm29 sera from ten vaccinated animals of each
group were tested by ELISA. Significant titers of specific anti-
Sm29 IgG antibodies were detected at all time points studied after
the first immunization (Figure 3). In order to determine the IgG
isotype profile induced by vaccination, specific anti-Sm29 IgG1
and IgG2a antibodies levels were also evaluated. The levels of
specific IgG1 and IgG2a increased at 15, 30 and 45 days after the
first immunization (Table 1). Furthermore, IgG1/IgG2a ratio was
reduced at days 30 and 45 that parallels with elevated anti-Sm29
IgG2a production. The IgG1/IgG2a ratio observed in mice
immunized with rSm29 can lead us to speculate that a Th1 type of
immune response was induced following vaccination.
Vaccination induces a Th1-type of immune response in
mice
Mice vaccinated with rSm29 showed elevated production of
IFN-c, TNF-a and IL-10 and absence of IL-4 (Table 2). Cultures
used for measuring the cytokines were treated with polymyxin B to
avoid non-specific stimulation due to eventual LPS contamination
in the purified recombinant protein [17]. Additionally, rSm29 has
stimulated peritoneal macrophages from C57BL/6 (20166
423 pg/ml) or TLR4 KO (11086197 pg/ml) mice to produce
IL-12 (Fig. 4). It is worth to emphasize that rSm29 has activated
macrophages to secrete IL-12 which drives Th1 cell development.
Protective immunity in mice against S. mansoni infection, before the
onset of egg production, is thought to be the result of a Th1
pattern of immune response [23].
rSm29 engenders protective immunity
To test the vaccine potential of rSm29 against schistosomiasis, we
investigated the protection induced by this recombinant antigen in
t h em u r i n em o d e lo fS. mansoni infection. C57BL/6 mice were
Sm29 Is a Protective Tegument Antigen of S. mansoni
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challenged with 100 S. mansoni cercariae. Control groups received
adjuvanted phosphate-buffered saline. Mice vaccinated with rSm29
showed 51% reduction in adult worm burden, 60% reduction in
intestinal eggs and 50% reduction in liver granuloma counts
compared to control mice (Table 2). The most critical points to be
considered about an efficient anti-schistosomiasis vaccine are the
reduction in pathology and transmission [7], aspects that are present
in the protection profile induced by rSm29 vaccine.
Gene expression profile in worms from vaccinated mice
In order to investigate the impact of rSm29 vaccination on S.
mansoni, worms that were recovered from vaccinated mice had their
gene expression profile analyzed using microarrays. This analysis
revealed significant (q,0.01) regulation of 517 genes (Table S1) in
worms recovered from mice vaccinated with adjuvanted rSm29
when compared to control mice injected with adjuvanted
phosphate-buffered saline; of these, 495 genes (96%) were down-
regulated and only 22 genes (4%) were up-regulated. Among down-
regulated genes, several of them caught our attention and they fell
into four major categories: tegument proteins (Sm23 and CD36-
like class B scavenger receptor), membrane proteins (tetraspanin
TE736), lipid metabolism (Sm14), receptor interacting proteins (B-
cell receptor-associated protein and TGF-beta receptor interacting
protein) and others (superoxide dismutase and Sm65) (Table 3). To
validate the microarray data, we selected six genes (Sm23, Sm14,
superoxide dismutase, CD36-like class B scavenger receptor, B-cell
receptor-associated protein and TGF-b receptor interacting
protein) and performed real-time RT-PCR. As demonstrated in
Figure 5, real-time RT-PCR of all six tested genes confirmed the
reduced expression previously determined by microarray analysis.
Based on the data shown in Table 3 and Figure 5, we hypothesize
that in rSm29 protected mice a reduced expression of these critical
surface antigens enables the parasites to adapt to the hostin the face
of an ongoing antiparasite immune response developed in
vaccinated animals.
Discussion
Schistosomiasis is one of the most important neglected tropical
diseases (NTDs), and an effective control is unlikely in the absence
of improved sanitation and a vaccine. Recently, the tegument
proteome of S. mansoni was characterized, and one study in
Figure 1. Immunolocalization of Sm29 antigen on male and female adult worm and lung-stage schistosomula of S. mansoni.
Polyclonal anti-Sm29 antibodies, serum from mice that received Freunds adjuvant as negative control, and Cy5-conjugated anti-mice IgG were used.
Actin was visualized by falloidin-Alexa fluor 488. The parasites were fixed in Omnifix II and used to whole-mount or section immunolocalization. (A
and B) Whole-mount immunolocalization of Sm29 antigen on the surface (outer tegument) of male adult worm and (C) lung-stage schistosomula of
S. mansoni. (D) Immunolocalization of Sm29 on the surface (outer tegument) of male adult worm, and (E) on the surface (outer tegument) and in
some internal tissues on the female adult worm using deparaffinized sections of the parasites. Localization of Sm29 is identified by the orange color
and actin filaments by the green color.
doi:10.1371/journal.pntd.0000308.g001
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adult parasites such as SmTSP-2 and Sm29 [11]. In this study, we
investigated murine humoral and cellular immune responses to
rSm29 and tested this molecule as a vaccine candidate.
The strategic localization of Sm29 in the mammalian skin-stage
and lung-stage schistosomula and its absence in cercariae suggests
that this antigen has an important role in the adaptation of the
parasite to the new environment when S. mansoni enters the
mammalian host. Previous studies using mice vaccinated with
irradiated cercariae showed that the lung is the key site of
elimination of this parasite [24]. Sm29 localization on the surface
of schistosomula is an important aspect of this antigen regarding its
protective properties.
In the mouse model, rSm29 induced high levels of anti-Sm29
IgG after the second immunization and showed reduced IgG1/
IgG2a ratio at 45 days after the first immunization (Table 1). This
finding suggests a tendency of a Th1 type of immune response
induced by rSm29 vaccination. Further, we confirmed by cytokine
analysis that rSm29 immunization elicited a Th1-type of immune
response characterized by high levels of IFN-c and no IL-4 and
51% of worm burden reduction. The involvement of IFN-c in
protective immunity to schistosomiasis is well documented in the
murine model [25]. In the irradiated cercariae vaccination model,
which induces high levels of protection, treatment with monoclo-
nal anti-IFN-c antibody totally abrogated the protective immunity
achieved [26]. Similar results were obtained using IFN-c knockout
mice exposed to the radiation-attenuated vaccine confirming the
essential role of IFN-c in protective immunity against murine
schistosomiasis [27]. Further, we tested the ability of rSm29 to
induce IL-12 in peritoneal macrophages of TLR4 KO mice.
TLR4 is the major receptor for macrophage activation by
bacterial LPS [28]. Therefore, using TLR4 KO we obviated any
possible effect of LPS contamination in IL-12 synthesis. In TLR4
KO mice, rSm29 has induced the production of large amounts of
IL-12 that is the key cytokine involved in Th1 cell development.
Pathology which results from granuloma formation around the
eggs in murine schistosomiasis is characterized by Th2-type of
Figure 2. Identification of Sm29 on skin-stage schistosomula
tegument by Western blot. Two micrograms of purified skin-stage
schistosomula tegument was applied onto 12% SDS-PAGE and transferred
to a nitrocellulose membrane by western blot. After that, the membrane
was probed with serum from rSm29 vaccinated mice or naı ¨ve animals
diluted 1:500 in TBST. Arrow indicates the native Sm29. The molecular
mass markers, from top to bottom, are: 97, 66, 45, 30, 20.1, and 14.4 kDa.
doi:10.1371/journal.pntd.0000308.g002
Figure 3. Kinetics of specific anti-Sm29 IgG induced in mice
immunized with rSm29. Sera of ten immunized mice per group were
collected at days 15, 30, 45, and 90 after the first immunization and
assayed by ELISA. Arrows indicate the timing of vaccination. Results are
presented as the mean absorbance measured at 492nm for each group.
Results represent the mean of two independent experiments.
Statistically significant differences of vaccinated mice compared to
PBS+adjuvant control group is denoted by one asterisk for (p,0.05).
doi:10.1371/journal.pntd.0000308.g003
Table 1. IgG1 and IgG2a immune profile induced by vaccination with recombinant Sm29.
Days
a Groups
IgG1 IgG2a IgG1/IgG2a ratio
Sm29 PBS Sm29 PBS Sm29
15 0.82160.559* 0.03460.022 0.22060.102* 0.01160.081 3.72
30 1.29060.326* 0.00660.068 0.63760.228* 0.04960.070 2.02
45 1.62360.159* 0.00660.007 0.81260.267* 0.03160.017 1.99
aDays after the first immunization
*Statistically significant compared to group of animals immunized with PBS with p,0.05
doi:10.1371/journal.pntd.0000308.t001
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neutralization of IL-4 [29]. Thus, morbidity and mortality in
murine schistosomiasis were hypothesized to be developed as a
direct consequence of the egg-induced Th2 type of immune
response. Herein, the intestinal egg numbers was reduced (60%)
following rSm29 vaccination compared to control group. Addition-
ally, the immune response elicited bySm29 was associated with 50%
reduction in granuloma counts. Since we detected IL-10 production
following splenocyte activation with rSm19, we hypothesize here
that this cytokine might be regulating Th2 responses and/or
preventing the development of highly polarized Th1 responses and
therefore, reducing inflammation and liver pathology [30,31].
In order to investigate the impact of rSm29 vaccination on S.
mansoni, worms that were recovered from vaccinated mice had
their gene expression profile analyzed using microarrays. In worms
recovered from mice vaccinated with adjuvanted rSm29 when
compared to a control group injected with adjuvanted phosphate-
buffered saline, 495 genes (96%) were down-regulated and only 22
genes (4%) were up-regulated. Among down-regulated genes,
many of them encode surface antigens and proteins associated
with immune signals suggesting that under immune attack
schistosomes reduce the expression of critical surface proteins.
We propose here that down-regulation of expression of important
surface antigens is an important strategy of the parasite resulting in
escape from host immune surveillance.
As observed in Table 3, Sm23, tetraspanin TE736 (a paralog of
Sm-TSP-2), Sm14, Sm65 and superoxide dismutase are signifi-
cantly (q,0.01) down-regulated in adult-worms recovered from
rSm29 protected mice; it is noteworthy that these genes encode
important schistosome antigens that are recognized by immune
mice and humans. Sm14 is able to induce cellular immune
responses in individuals from endemic areas for schistosomiasis
[32]. Sm23 and Sm65 are antigens recognized by sera from
schistosome infected patients [33,34]. Moreover, Sm14 and Sm23
induce partial protection in the murine model for schistosomiasis
[35,36]. Regarding tetraspanins, they belong to a family of
membrane proteins, such as Sm-TSP-2, that is currently one of the
most important vaccine candidates for schistosomiasis [37].
Further, vaccination of mice with naked DNA construct
containing Cu/Zn cytosolic superoxide dismutase showed signif-
icant levels of protection compared to a control group [38].
It is noteworthy that no significant up-regulation of heat shock
or chaperone genes was detected in schistosomes recovered from
rSm29 vaccinated mice (Table S1), therefore excluding a common
stress response. Rather, lowering the expression of critical surface
antigens seems to be an important and specific strategy developed
by schistosomes to reduce the damage caused by the host immune
Figure 4. Sm29 induces IL-12 and TNF-a production by
macrophages from TLR4 knockout mice. Levels of IL-12 (p40) (A)
or TNF-a (B) were measured in the supernatants of inflammatory
macrophages from TLR4 KO or wild-type mice stimulated for 24 hrs with
rSm29 (25 mg/ml), E. coli LPS (1 mg/ml) or medium alone. Significant
differences from stimulated TLR4 KO or C57BL/6 macrophages in relation
to non-stimulated cells are denoted by an asterisk (*) for p,0.05.
doi:10.1371/journal.pntd.0000308.g004
Table 2. Parasitologic data, cytokine profile, intestinal egg counts and liver granuloma analysis of C57BL/6 mice vaccinated with
rSm29 and challenged with 100 Schistosoma mansoni cercariae.
Groups
a
Cytokine profile in
splenocytes (pg/ml)
Male worms
Mean6SD
Female worms
Mean6SD
Total worms
Mean6SD (%
protection)
Intestinal eggs
Mean6SD (%
reduction)
Number of granulomas/
liver tissue mm
2 10
27
Mean6SD (% reduction)
PBS+CFA/IFA IL-4 7.863.0 28.268.1 29.466.4 57.7612.2 16110.365755.2 6.7461.3
IFN-c 31.265.1
TNF-a 15.664.2
IL-10 31.363.1
rSm29+CFA/IFA IL-4 7.864.6 14.661.7 15.164.7 29.765.3* (51%) 6440.463644.2* (60%) 3.360.6* (50%)
IFN-c 2538.3644.6 *
TNF-a 426.36231.5*
IL-10 425.2692.2*
aThis Table shows one experiment representative of two independent trials with similar results
*Statistically significant compared to the control group (p,0.05)
doi:10.1371/journal.pntd.0000308.t002
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and one or more of the proteins encoded by these down-regulated
critical surface antigens might be the next logical step, thus
circumventing the adaptive response of the parasite and eventually
boosting the protective effect of vaccination.
Among the down-regulated genes (Table 3) were those encoding
protein domains from TGF-b receptor interacting protein, B-cell
receptor-associated protein, CD36-like class B scavenger receptor,
all of which are associated with host immune response. These
parasite gene products could interact with or modulate the host
immune response. For example, the scavenger receptors are
present on different cells such as macrophages, platelets and
neutrophils where they are involved with innate immunity by
facilitating phagocytosis, cell adhesion and pathogen recognition.
Recently, it was demonstrated that schistosome CD36-like class B
scavenger receptor binds to host low density lipoproteins [39].
From the parasite perspective, it would not be difficult to envisage
that a reduced expression of S. mansoni scavenger receptor-like
Table 3. Putative identity, categories of biological function and fold change of a subset of down-regulated genes identified in
worms recovered from animals vaccinated with rSm29 associated to adjuvant.
Contig Putative identity
Fold Change
a Down-regulation
with rSm29 plus adjuvant
Tegument proteins
C600716.1 CD36-like class B scavenger receptor [S. mansoni] 1.7
C605987.1 Integral membrane protein/sugar transporter family [B. vulgaris] 2.1
C601295.1 Sm23 kDa integral membrane protein [S. mansoni] 2.0
C607243.1 Alkaline phosphatase [M. musculus] 3.1
C610121.1 Annexin [S. mansoni] 2.0
Membrane proteins
C604563.1 Tetraspanin TE736 [S. japonicum] 2.1
C609525.1 Transmembrane protein 49 [X. tropicalis] 2.6
C605890.1 ATPase, aminophospholipid transporter [B. Taurus] 1.9
C606907.1 Putative insulin receptor [E. multilocularis] 1.8
C609637.1 vacuolar proton pump [Danio rerio] 1.8
C609954.1 Autocrine motility factor receptor [T. castaneum] 1.5
C608609.1 Voltage-dependent anion channel 1 [X. laevis] 1.6
C601007.1 UDP dual transporter [C. elegans] 2.0
C609782.1 DAD-1-like protein/integral membrane [S. japonicum] 1.9
Receptors interacting proteins
C610202.1 Serine/threonine kinase receptor associated protein [P. troglodytes] 1.6
C607204.1 Thyroid receptor interacting protein 13 [H. sapiens] 1.7
C603157.1 syndecan binding protein (syntenin) [D. rerio] 1.5
C606116.1 G protein beta subunit [P. fucata] 2.1
C600861.1 B-cell receptor-associated protein-like protein [S. mansoni] 1.5
C608810.1 rhoGAP protein [M. domestica] 2.7
C714516.1 TGF-beta receptor interacting protein 1 [C. sinensis] 1.8
Lipid metabolism
C601385.1 SmINSIG [S. mansoni] 2.3
C601665.1 Fatty acid-binding protein Sm14 [S. mansoni] 1.5
C608771.1 Very low density lipoprotein binding protein [S. japonicum] 1.8
C711918.1 Fatty acid coenzyme A ligase 5 [H. sapiens] 1.7
Other
C602958.1 Apoferritin-2 [S. japonicum] 1.7
C610848.1 Ferritin heavy chain 2 [S. mansoni] 2.1
C601146.1 IB1 protein [S. japonicum] 2.9
C608351.1 Tropomyosin [S. mansoni] 1.7
C600304.1 src tyrosine kinase [S. mansoni] 1.7
C603876.1 PrA2 protein [S. mansoni] 1.7
C607402.1 Superoxide dismutase [S. mansoni] 1.5
C604746.1 Sm65 antigen [S. mansoni] 1.5
astatistically significant, q,0.01
doi:10.1371/journal.pntd.0000308.t003
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by host cells.
Additionally, we found down-regulated genes involved with
parasite carbohydrate and lipid metabolism, protein biosynthesis,
intracellular signaling cascade, among others (Table S1). Down-
regulated genes include SmINSIG (an ortholog of the mammal
Insulin Induced Gene), a recently described gene in S. mansoni [40]
that has a key role in HMG-CoA reductase degradation. HMG-
CoA reductase is vital for egg production by S. mansoni [41]. An
alternative hypothesis to our findings is that down-regulation of
these genes may affect the development or survival of parasites in
vaccinated animals, thus reducing worm burden, although the
worms recovered from mice vaccinated with adjuvanted rSm29
are morphologically similar to those recovered from control mice.
Additionally, haemoglobinases and Sm29 gene expression were
unaltered in worms recovered from rSm29 immunized animals.
Recently, Dillon et al [42] in an attempt to identify antigens
responsible for protection induced by irradiated-cercariae vacci-
nation performed microarray expression analysis of irradiated and
normal worms. These investigators detected down-regulation of
genes involved in neuromuscular activity and cell cycle. Their
hypothesis is that attenuated parasite might have an extended stay
in the host enhancing immune priming against exposed antigens
[42]. Their findings may explain why irradiated-cercariae can
elicit protective immunity when normal cercariae do not.
Recent advances in antigen discovery with preclinical studies
showing promising efficacy have reinvigorated the case for a
schistosomiasis vaccine. The irradiated-cercariae vaccine and the
use of recombinant antigens, such as Sm-TSP-2 and Sm29, that
induce approximately 50% worm burden reduction, have
demonstrated that a vaccine to schistosomes is achievable [37].
Furthermore, we identified an ortholog of Sm29 in the ESTs of the
Asian schistosome S. japonicum that shares more than 50% identity
in the amino acid sequence, indicating that a vaccine based on
Sm29 might also be effective against S. japonicum [43]. Another
important issue is the selection of a suitable adjuvant and/or
delivery system to induce the appropriate immune responses.
Herein, we used rSm29 with Freunds adjuvant, however, it is not
suitable for human application. Experiments are underway testing
rSm29 with CpG or CpG plus alum as suggested by McManus &
Loukas [44]. As a final conclusion of this work, we believe that
Sm29 is an efficient vaccine candidate against schistosomiasis in
light of the data obtained from murine studies. The best long-term
strategy to control schistosomiasis might be immunization with
anti-Sm29 vaccine associated with other protective surface
antigens and possibly combined with drug treatment.
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